The Medicines Evaluation Board (MEB) invites interested parties and stakeholders to comment on 2 amended policy documents on the labeling of medicines for humans (MEB 6) and the naming of pharmaceutical products (MEB 13).
The most important changes are described on the website of the MEB for both documents. Besides some corrections following new requirements (e.g. safety features according to FMD), restrictions for the graphics to be used on the packaging are suggested. For the naming of medicinal products, clarifications are suggested to prevent any promotional aspects in the name of medicines and to improve the combination products and combination packagings.